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0032-3 Late (Two-Year) Follow-Up From the First-in-Man (FM) 
Experience After Implantation of Sirolimus-Eluting 
Stents 
Jose, Alexandre Abizaid, Andrea Abizaid. Jeffrey Popma, Pim de Feyter, 
Fausto Feres, Marco Costa. Judith Jaeger, Luiz F. Tanajura, Ana C. S&as, lbraim Pinto, 
Luiz A. Mattes, Robert Falotico, Martin Leon, Patrick Serruys. Amanda Sousa, Institute 
Dante F’azzanese of Cardiobg~ Sao Pm/o, Brazil. 
Background: Exciting short-term (4-months) and intenediate-term (i-year) results after 
implantation of sirolimus-eluting (Cyphertr”) stent in human coronary arteries have been 
reported. Between 4 to 12 months clinical and angiographic restenosis was still 0%. fol- 
low-up MLD showed minimal changes from 2.62M.16mm at 4 months to 2.43M.19mm 
at 12 months, and IVUS percent obstruction volume increased minimally from 0.3fo.8% 
to 2.2*3.4%. The aim of this study is to determine if deleterious pathobiolcgic responses 
are present after a long (Pyear) follow-up. Mathods: Thirty patients treated with 
Cyphertm stents for single de ncvo coronary lesions (15 fast-release and 15 slow-release 
formulation) will complete 2.year follow-up in February, 2002. Repeat quantitatwe 
angiography. clinical outcomes assessments, and volumetric IVUS analysis will be per- 
formed. Resufts: At present (21f2 months) there has been one MACE (3.3%) at 14 
months due to non-target site coronary occlusion proximal to the Cypherrm stent resulting 
in acute MI. Serial IVUS interrogation of this MI culprit lesion demonstrated plaque pro- 
gression with echo-lucent zones suggesting plaque instability. For the entire patient 
cohort, there was no deaths and no target lesion revasculartzation events. Conclusion: 
Thusfar, in the FIM experience. the sirolimus-eluting Cypherrm stent has demonstrated 
striking safety and efficacy up to one-year follow-up, with no restenosis or repeat revas- 
cularization events, and complete elimination of stent associated neointimal hyperplasia. 
The P-year follow-up results (available for presentation) should definitively establish sus- 
tained suppression of the restenosis process and long-term safety. 
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0032-4 Beta Versus Gamma Radiation for Treatment of Indtent 
Restenosis: Angiographic Predictors and Outcomes in 
630 Patients 
BShirai. Alexandra J. Lansky, Roxana Mehran, Kartik Desai, Costantino 
Costantini-Ortiz, Brian Proctor, Teraza Conway, Martin Fahy, Nishe Dave, lzat Hjazi. 
George Dangas, Gregg W. Stone, Paul Teirstein, Jeffrey Moses, Martin 8. Leon, 
Cardiovascular Research Foundation, New York. 
Background: Randomized trials have demonstrated striking efficacy of Gamma and Beta 
radiation compared to placebo in the treatment of in-stent restenosis (ISR). Methods: To 
compare the outcomes of Gamma vs Beta radiation we reviewed the angiographic 
results of 630 pts (N=227 Gamma; N=177 Beta: N=226 placebo) with native coronary 
ISR matched for ACC/AHA lesion complexity, lesion length and vessel size. QCA was 
performed prospectively by analysts blinded to treatment allocation, using standardized 
methodology. Results: The mean lesion length was 15.54+/-661mm and the vessel size 
2.49+/-0.33mm. Final QCA results were similar in the 3 groups (final MLD 1.67+/-0.36 
and fmal %DS 26%). Follow-up results in table. By multivariable analysis, independent 
angiographic predictors of treated segment restenosis among radiation pts included 
lesion length (OR 1.024, p=O.OOa) and vessel size (OR 0.494, p=O.OOl). Conclusion: In 
pts with matched lesion characteristics, gamma and beta radiation achieve a similar 
reduction in treated segment restenosis compared to placebo. Given the current isotope 
dosimetries, the relative reduction after Beta radiation is greatest within the stent at the 
expense of more stent edge restenosis, whereas with Gamma radiation the relative 
reduction within the stent is less pronounced, but stent edge restenosis is also less fre- 
quent. 
Follow-up results 
Treated Segment Restenosis, % 
InStent Restenosis, % 
Stent Edoe Restenosis. % 
Gamma Beta Placebo P Value 
33.5 30.0 53.9 <0.0001 
24.7 16.9’ 50.0 <0.0001 
9.3 17.1” 4.4 0.0001 
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0032-5 Quantitative Angiographic Findings of the PREDICT 
Trial: A Randomized Clinical Trial Comparing a Strategy 
of Predilatation Prior to Stent Placement Versus Direct 
Stenting 
Ross, Jeffrey J. Popma, Nicholas Cox. Michelle Fitzpatrick. Azin Parhizgar, Richard 
E. Kuntz. Donald S. Bairn, Harvard Clinical Research Institute, Boston, Massachusetts. 
Background: High pressure direct stenting has potential advantages over traditional 
deployment strategies (predilatation, stent deployment +I- post dilatation), including 
reductions in consumable costs, radiation exposure, contrast load and procedure time. 
Methods: Four hundred patients were randomized to either direct stenting with the AVE 
S670TM stent or predilatation followed by S670TM deployment in native coronary artery 
lesions. Baseline angiographic and clinical date were collected, with clinical follow-up at 
14 and 30 days and 6 months, and angiographic follow-up at 6 months. Findings: Pri- 
mary Device Success (~50% residual stenosis at target site using assigned treatment 
strategy) was achieved in 92.6% of patients undergoing direct stenting compared with 
96.0% in those with lesion predilatation (P=O.O56). Quantitative angiographic findings are 
demonstrated below. There were no significant differences at baseline, post procedure or 
follow up. and the restenosis rate was similar in both groups (20.4% in direct stenting 
group versus 20.9% in controls P=l .O). Incidence of major complications including abrupt 
and subacute closure and stent thrombosis was low in both groups. as was significant 
dissection (Type C or greater, 1.5% both groups). 
Lesion Characteristics (Mean+SD) Direct Stentlng Pre-Dilatation 
(N=198 Patients, (N=201 Patlents, P-vatue 
N=201 Lesions) N=203 Leslons) 
Basellne 
ACCIAHA Lesion Class 
A 
Bl 
82 
C 
Lesion Length (mm) 
Reference Vessel Diameter (mm) 
Minimal Lumen Diameter (mm) 
% Diameter Stenosis 
Post-Procedure 
Reference Vessel Diameter (mm) 
Minimal Lumen Diameter (mm) 
% Diameter Stenosis 
Acute Gain (mm) 
Follow-Up 
Reference Vessel Diameter (mm) 
Minimal Lumen Diameter (mm) 
% Diameter Stenosis 
Late Loss 
Late Loss Index 
Binary Restenosis Rate 
Abrupt Closure to 160 days 
6.1% 
44.2% 
40.7% 
7.0% 
11.96f4.67 
2.91fo.60 
0.9433.46 
67.6%f14.0% 
3.13i6.55 
2.92+6.43 
5.9%f9.4% 
1.96i0.53 
2.65M.54 
1.95fo.71 
31.6%M2.1% 
0.96M.61 
0.51M.35 
20.4% (33 / 162) 
11 .O% 0.594 
35.6% 0.331 
45.2% 0.630 
6.2% 0.773 
11.41M.10 0.425 
2.90*0.52 0.662 
0.90*0.45 0.367 
69.2%*12.9% 0.216 
3.15io.55 0.771 
2.9&0.42 0.165 
4.5%*9.3% 0.150 
2.06+0.52 0.056 
2.64kO.46 0.611 
1.93io.73 0.717 
32.5%?22.2% 0.714 
1.06*0.66 0.240 
0.52+0.32 0.755 
20.9% (34 Il63) 1.000 
0.0% 1.5% 0.246 
Subacute Closure to 160 days 0.0% 0.5% 1.000 
Stent Thrombosis to 160 days 0.5% 0.5% 1.000 
Conclusions: Direct stenting using the AVE S670” is associated with high acute prcce- 
dural success and low rates of angiographic complications and binary restenosis, equiv- 
alent to those seen with conventional predilatation and stenting. 
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‘p=O.164 and ** p=O.O16 for gamma versus beta. 
